Jean-François Huon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jean-François Huon has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Evin
Nantes Université, CHU Nantes, Service de Soins Palliatifs et de Support, Nantes, France
8 shared publications - Pierre Nizet
Nantes Université, CHU Nantes, Pharmacie France
8 shared publications Pierre Nizet
Nantes Université, CHU Nantes, Nantes, France
5 shared publicationsCaroline Victorri-Vigneau
Nantes Université, Tours Université, CHU Nantes, CHU Tours, INSERM, Methods in patients-centered outcomes and Health Research, SPHERE, Nantes, France
4 shared publicationsDominique Navas
Nantes Université, CHU Nantes, Pharmacie, Nantes, France
4 shared publicationsCharlotte Grivel
Nantes Université, CHU Nantes, Pharmacie, Nantes, France
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in BMC Medicine
Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit
Background: Continuous deep sedation until death (CDSUD) is a legally regulated practice in France relying primarily on midazolam as first-line therapy. However, additional sedative agents are frequently required, and determinants of failure of midazolam monotherapy remain poorly understood. This study aimed to identify factors associated with failure of midazolam monotherapy during CDSUD, defined as the need for second- or third-line sedative agents. Methods: We conducted a retrospective single-centre observational study including all patients undergoing CDSUD in a university hospital palliative care unit between 2020 and 2024. Demographic, clinical, pharmacological, and organisational data were collected. Associations with failure of midazolam monotherapy were assessed using univariable and multivariable logistic regression. Age was modelled using restricted cubic splines to account for non-linear effects. Results: Among 1,376 patients admitted to the unit, 287 underwent CDSUD with midazolam as first-line treatment. Median age was 69 years (IQR 59–77), and 52.3% were male. Cancer was the main diagnosis (74.2%). Failure of midazolam monotherapy occurred in 211/287 patients (73.5%). Among these patients, escalation consisted of chlorpromazine alone in 134/211 patients (63.5%), propofol alone in 20/211 patients (9.5%), and both agents in 57/211 patients (27%). In multivariable analysis, polypharmacy was independently associated with an increased risk of failure of midazolam monotherapy ( P= .002), both in patients receiving 5–9 medications (OR 3.06, 95% CI 1.60–5.91) and in those receiving ≥ 10 medications (OR 3.05, 95% CI 1.22–8.11). Sedation performed in the context of withdrawal of life-sustaining treatment was also associated with failure of midazolam monotherapy (OR 3.51, 95% CI 1.46–9.88). Age showed a significant non-linear association with outcome ( P <.001). Oxygen therapy within the 24 h preceding sedation induction was associated with a reduced risk of failure (OR 0.35, 95% CI 0.18–0.65). Conclusions: Failure of midazolam monotherapy during CDSUD is common and associated with polypharmacy, and specific clinical contexts. The non-linear effect of age highlights complex pharmacological responses at end of life. These findings support individualized sedation strategies and early anticipation of combination therapy.
- 5 October 2026
- Published by Springer Nature in BMC Medicine
Open AccessDeterminants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit
Background: Continuous deep sedation until death (CDSUD) is a legally regulated practice in France relying primarily on midazolam as first-line therapy. However, additional sedative agents are frequently required, and determinants of failure of midazolam monotherapy remain poorly understood. This study aimed to identify factors associated with failure of midazolam monotherapy during CDSUD, defined as the need for second- or third-line sedative agents. Methods: We conducted a retrospective single-centre observational study including all patients undergoing CDSUD in a university hospital palliative care unit between 2020 and 2024. Demographic, clinical, pharmacological, and organisational data were collected. Associations with failure of midazolam monotherapy were assessed using univariable and multivariable logistic regression. Age was modelled using restricted cubic splines to account for non-linear effects. Results: Among 1,376 patients admitted to the unit, 287 underwent CDSUD with midazolam as first-line treatment. Median age was 69 years (IQR 59–77), and 52.3% were male. Cancer was the main diagnosis (74.2%). Failure of midazolam monotherapy occurred in 211/287 patients (73.5%). Among these patients, escalation consisted of chlorpromazine alone in 134/211 patients (63.5%), propofol alone in 20/211 patients (9.5%), and both agents in 57/211 patients (27%). In multivariable analysis, polypharmacy was independently associated with an increased risk of failure of midazolam monotherapy ( P= .002), both in patients receiving 5–9 medications (OR 3.06, 95% CI 1.60–5.91) and in those receiving ≥ 10 medications (OR 3.05, 95% CI 1.22–8.11). Sedation performed in the context of withdrawal of life-sustaining treatment was also associated with failure of midazolam monotherapy (OR 3.51, 95% CI 1.46–9.88). Age showed a significant non-linear association with outcome ( P <.001). Oxygen therapy within the 24 h preceding sedation induction was associated with a reduced risk of failure (OR 0.35, 95% CI 0.18–0.65). Conclusions: Failure of midazolam monotherapy during CDSUD is common and associated with polypharmacy, and specific clinical contexts. The non-linear effect of age highlights complex pharmacological responses at end of life. These findings support individualized sedation strategies and early anticipation of combination therapy.
- Open Access
- 23 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (5) , e72563
Systematic Management of a Critical CYP3A4 Interaction Between Cabozantinib and Carbamazepine: A Case Report of a Clinically Relevant Pharmacokinetic Interaction
This was the case of a 62‐year‐old patient treated with cabozantinib and nivolumab for metastatic clear cell renal cell carcinoma, in whom a clinically significant pharmacokinetic interaction with carbamazepine was observed. Carbamazepine, a potent inducer of CYP3A4, caused a major decrease in systemic exposure to cabozantinib, as confirmed by a residual plasma concentration well below the therapeutic target. An adaptation strategy based on identifying the interaction, gradually replacing carbamazepine with a noninducing anticonvulsant, temporarily adjusting the cabozantinib dosage, and close pharmacokinetic monitoring made it possible to restore effective concentrations without toxicity or neurological decompensation. This optimization was accompanied by a significant clinical improvement and radiological tumor control. This case has led to the ongoing need for a medication review before initiating this type of cancer treatment and the implementation of pharmacokinetic monitoring when an interaction was detected.
- 23 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (5) , e72563
Open AccessSystematic Management of a Critical CYP3A4 Interaction Between Cabozantinib and Carbamazepine: A Case Report of a Clinically Relevant Pharmacokinetic Interaction
This was the case of a 62‐year‐old patient treated with cabozantinib and nivolumab for metastatic clear cell renal cell carcinoma, in whom a clinically significant pharmacokinetic interaction with carbamazepine was observed. Carbamazepine, a potent inducer of CYP3A4, caused a major decrease in systemic exposure to cabozantinib, as confirmed by a residual plasma concentration well below the therapeutic target. An adaptation strategy based on identifying the interaction, gradually replacing carbamazepine with a noninducing anticonvulsant, temporarily adjusting the cabozantinib dosage, and close pharmacokinetic monitoring made it possible to restore effective concentrations without toxicity or neurological decompensation. This optimization was accompanied by a significant clinical improvement and radiological tumor control. This case has led to the ongoing need for a medication review before initiating this type of cancer treatment and the implementation of pharmacokinetic monitoring when an interaction was detected.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Mise au point d’un modèle murin de plaie diabétique chronique infectée à S. aureus et évaluation de l’impact d’une application locale de bactériophages
Les infections des plaies de pied diabétique sont difficiles à traiter du fait des artériopathies diminuant la diffusion des antibiotiques jusqu'à leur cible. De plus, l'augmentation des résistances bactériennes engendre des impasses thérapeutiques pouvant conduire à l'amputation. Afin de développer des alternatives thérapeutiques, la mise au point d'un modèle animal était nécessaire. Nous avons développé un modèle murin de plaie diabétique chronique infectée à S. aureus. Ce modèle a permis de mimer une plaie restant ouverte et infectée par 109 bactéries/g de tissu au 14e jour de l'infection. La mesure de cytokines cutanées a mis en évidence une augmentation de l'IL-17 et un effondrement de l'IL-10, témoignant du profil inflammatoire. Secondairement, l’application locale à 48h de l'infection d’une suspension de phages a été comparée à une administration per os d'amoxicilline/clavulanate durant 5 jours, et à l'association des 2 traitements. Les résultats ont montré une meilleure survie des animaux dans les 3 bras traités vs. contrôle. La diminution de la charge bactérienne de la plaie a été la plus importante dans le bras traité par phages seuls, puis dans le bras traité par l'association. La charge bactérienne des souris traitées par antibiotique seul était peu diminuée. La mesure de l'IL-17 et de l'IL-10 cutanées n'a pas mis en évidence de différence significative entre les différents traitements. L'impact sur le microbiote intestinal est encore en cours d'évaluation. Notre modèle sera utile à la mise au point d'alternatives aux traitements conventionnels des plaies diabétiques infectées. L'utilisation topique de bactériophages semble être une piste prometteuse.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Mise au point d’un modèle murin de plaie diabétique chronique infectée à S. aureus et évaluation de l’impact d’une application locale de bactériophages
Les infections des plaies de pied diabétique sont difficiles à traiter du fait des artériopathies diminuant la diffusion des antibiotiques jusqu'à leur cible. De plus, l'augmentation des résistances bactériennes engendre des impasses thérapeutiques pouvant conduire à l'amputation. Afin de développer des alternatives thérapeutiques, la mise au point d'un modèle animal était nécessaire. Nous avons développé un modèle murin de plaie diabétique chronique infectée à S. aureus. Ce modèle a permis de mimer une plaie restant ouverte et infectée par 109 bactéries/g de tissu au 14e jour de l'infection. La mesure de cytokines cutanées a mis en évidence une augmentation de l'IL-17 et un effondrement de l'IL-10, témoignant du profil inflammatoire. Secondairement, l’application locale à 48h de l'infection d’une suspension de phages a été comparée à une administration per os d'amoxicilline/clavulanate durant 5 jours, et à l'association des 2 traitements. Les résultats ont montré une meilleure survie des animaux dans les 3 bras traités vs. contrôle. La diminution de la charge bactérienne de la plaie a été la plus importante dans le bras traité par phages seuls, puis dans le bras traité par l'association. La charge bactérienne des souris traitées par antibiotique seul était peu diminuée. La mesure de l'IL-17 et de l'IL-10 cutanées n'a pas mis en évidence de différence significative entre les différents traitements. L'impact sur le microbiote intestinal est encore en cours d'évaluation. Notre modèle sera utile à la mise au point d'alternatives aux traitements conventionnels des plaies diabétiques infectées. L'utilisation topique de bactériophages semble être une piste prometteuse.
- Open Access
- 5 February 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (1) , 103466
Development of a shared decision-making tool for systemic treatment in psoriasis
- 5 February 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (1) , 103466
Open AccessDevelopment of a shared decision-making tool for systemic treatment in psoriasis
- 23 January 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 138 (2) , e70196
Evaluation of the Perception of Deprescribing by French Pharmacy Students: A National Observational Study
The ageing population, which is often associated with polypharmacy, indicates the need for evolution within the healthcare professions. Future pharmacists must develop new skills and knowledge to meet these challenges, including during their university training. Deprescribing is an essential process for optimising drug intake and reducing the risks associated with polypharmacy, although the term remains little known in France. This study aims to assess the perceptions of pharmacy students regarding deprescribing, and to identify their training needs. A questionnaire based on an American study was distributed. Composed of seven sections, it covered knowledge, confidence, attitudes, the interprofessional role, the required resources, as well as preparedness for deprescribing and sociodemographic data. A total of 407 responses were analysed, along with the qualitative results of two open‐ended questions, which were processed using thematic analysis. The results showed that, whereas 66.2% of students felt able to identify potentially inappropriate medicines (PIMs), only 29.6% expressed confidence in their ability to deprescribe these medications. While 97.5% recognised the value of deprescribing PIMs, 88.6% identified numerous obstacles to its implementation. These results highlight the need to adapt pharmacy student training to enhance their skills and confidence in this area.
- 23 January 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 138 (2) , e70196
Evaluation of the Perception of Deprescribing by French Pharmacy Students: A National Observational Study
The ageing population, which is often associated with polypharmacy, indicates the need for evolution within the healthcare professions. Future pharmacists must develop new skills and knowledge to meet these challenges, including during their university training. Deprescribing is an essential process for optimising drug intake and reducing the risks associated with polypharmacy, although the term remains little known in France. This study aims to assess the perceptions of pharmacy students regarding deprescribing, and to identify their training needs. A questionnaire based on an American study was distributed. Composed of seven sections, it covered knowledge, confidence, attitudes, the interprofessional role, the required resources, as well as preparedness for deprescribing and sociodemographic data. A total of 407 responses were analysed, along with the qualitative results of two open‐ended questions, which were processed using thematic analysis. The results showed that, whereas 66.2% of students felt able to identify potentially inappropriate medicines (PIMs), only 29.6% expressed confidence in their ability to deprescribe these medications. While 97.5% recognised the value of deprescribing PIMs, 88.6% identified numerous obstacles to its implementation. These results highlight the need to adapt pharmacy student training to enhance their skills and confidence in this area.
- Open Access
- 5 November 2025
- Published by Elsevier in Le Pharmacien Clinicien
- Vol. 61 (1) , 62-65
Référentiel de compétences « Méthodologie de Pharmacie Clinique » à destination des enseignants
- 5 November 2025
- Published by Elsevier in Le Pharmacien Clinicien
- Vol. 61 (1) , 62-65
Open AccessRéférentiel de compétences « Méthodologie de Pharmacie Clinique » à destination des enseignants
- Open Access
- 1 July 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-10
Use of brief, simple anxiety assessment tools in palliative care – yes, we can: a cross-sectional observational study of anxiety visual analog scale and numeric rating scale
Background: Given the high prevalence of anxiety in palliative care and its frequent underestimation by healthcare professionals, it is important to use simplified tools to facilitate the evaluation of anxiety. The State-Trait Anxiety Inventory–State scale is a reference 20-item questionnaire that has been validated in this population, but is too long for some patients. The visual analog scale (VAS) and the numeric rating scale (NRS) are two short instruments that have been validated to assess pain, but not anxiety in palliative care. Aim: This study sought to investigate the correlation between anxiety VAS and NRS and State-Trait Anxiety Inventory-State scale for assessing anxiety in palliative care patients. Methods: A single-center cross-sectional observational study was conducted over 2 years. All palliative care patients followed by the palliative care team of a French university hospital were eligible. Each patient completed the State-Trait Anxiety Inventory-State scale and rated their perceived anxiety using the NRS and VAS. Pearson’s correlation test between the scales and receiver operating characteristic (ROC) curve analysis were performed to determine diagnostic cut-offs. Results: A total of 186 patients were included (89.8% with cancer), 20.4% of whom had severe or very severe anxiety. The NRS/ State-Trait Anxiety Inventory–State scale and VAS/ State-Trait Anxiety Inventory–State scale correlations were 0.62 and 0.70, respectively. The NRS and VAS showed good discrimination, with an area under the ROC curve of 0.81 and 0.88, respectively. Cut-offs of 5 (NRS) and 49 millimeters (VAS) yielded sensitivities of 89.5% and 89.2%, respectively, for the detection of severe or very severe anxiety, with specificities of 60.1% and 70.3%, respectively. Conclusion: Cut-offs of 5 for the NRS and 49 millimeters for the VAS showed excellent sensitivity for detecting anxiety in palliative care.
- 1 July 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-10
Open AccessUse of brief, simple anxiety assessment tools in palliative care – yes, we can: a cross-sectional observational study of anxiety visual analog scale and numeric rating scale
Background: Given the high prevalence of anxiety in palliative care and its frequent underestimation by healthcare professionals, it is important to use simplified tools to facilitate the evaluation of anxiety. The State-Trait Anxiety Inventory–State scale is a reference 20-item questionnaire that has been validated in this population, but is too long for some patients. The visual analog scale (VAS) and the numeric rating scale (NRS) are two short instruments that have been validated to assess pain, but not anxiety in palliative care. Aim: This study sought to investigate the correlation between anxiety VAS and NRS and State-Trait Anxiety Inventory-State scale for assessing anxiety in palliative care patients. Methods: A single-center cross-sectional observational study was conducted over 2 years. All palliative care patients followed by the palliative care team of a French university hospital were eligible. Each patient completed the State-Trait Anxiety Inventory-State scale and rated their perceived anxiety using the NRS and VAS. Pearson’s correlation test between the scales and receiver operating characteristic (ROC) curve analysis were performed to determine diagnostic cut-offs. Results: A total of 186 patients were included (89.8% with cancer), 20.4% of whom had severe or very severe anxiety. The NRS/ State-Trait Anxiety Inventory–State scale and VAS/ State-Trait Anxiety Inventory–State scale correlations were 0.62 and 0.70, respectively. The NRS and VAS showed good discrimination, with an area under the ROC curve of 0.81 and 0.88, respectively. Cut-offs of 5 (NRS) and 49 millimeters (VAS) yielded sensitivities of 89.5% and 89.2%, respectively, for the detection of severe or very severe anxiety, with specificities of 60.1% and 70.3%, respectively. Conclusion: Cut-offs of 5 for the NRS and 49 millimeters for the VAS showed excellent sensitivity for detecting anxiety in palliative care.
- Open Access
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (11) , 3530-3540
The cost of potentially inappropriate medications for older adults in Canada: A comparative cross‐sectional study
Background: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. Methods: This was a cross‐sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation‐adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. Results: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). Conclusions: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (11) , 3530-3540
Open AccessThe cost of potentially inappropriate medications for older adults in Canada: A comparative cross‐sectional study
Background: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. Methods: This was a cross‐sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation‐adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. Results: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). Conclusions: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.
- 28 August 2024
- Published by Wiley in Pain Practice
- Vol. 25 (1)
Determinants of successful opioid deprescribing: Insights from French pain physicians—A qualitative study
Background: Long‐term use of opioids does not result in significant clinical improvement and has shown more adverse than beneficial effects in chronic pain conditions. When opioids cause more adverse effects than benefits for the patient, it may be necessary to initiate a process of deprescribing.Aim: To explore the perceptions of French pain physicians regarding the process of opioid deprescribing in patients experiencing chronic non‐cancer and to generate an understanding of the barriers and levers to the deprescribing process.Methods: We conducted a multicentric observational study with qualitative approach. Individual semi‐structured interviews exploring pain physicians' perceptions, beliefs, and representations to assess the determinants of opioid deprescribing with an interview guide were used. After checking the transcripts, an inductive and independent thematic analysis of the interviews was to extract meaningful themes from the dataset.Results: Twelve pain physicians were interviewed. The main obstacles to deprescribing revolved around patient‐specific attributes, characteristics of the opioids themselves, and limitations within the current healthcare system, that hinder optimal patient management. Conversely, patient motivation and education, recourse to hospitalization in a Pain Department with multidisciplinary care, follow‐up by the general practitioner, and training and information dissemination among patients and clinicians emerged as facilitative elements for opioid deprescribing.Conclusion: This study underscores the needs to improve the training of healthcare professionals, the effective communication of pertinent information to patients, and the establishment of a therapeutic partnership with the patient. It is therefore essential to carry out the deprescribing process in a collaborative and interprofessional manner, encompassing both pharmaceutical and non‐pharmaceutical strategies.
- 28 August 2024
- Published by Wiley in Pain Practice
- Vol. 25 (1)
Determinants of successful opioid deprescribing: Insights from French pain physicians—A qualitative study
Background: Long‐term use of opioids does not result in significant clinical improvement and has shown more adverse than beneficial effects in chronic pain conditions. When opioids cause more adverse effects than benefits for the patient, it may be necessary to initiate a process of deprescribing.Aim: To explore the perceptions of French pain physicians regarding the process of opioid deprescribing in patients experiencing chronic non‐cancer and to generate an understanding of the barriers and levers to the deprescribing process.Methods: We conducted a multicentric observational study with qualitative approach. Individual semi‐structured interviews exploring pain physicians' perceptions, beliefs, and representations to assess the determinants of opioid deprescribing with an interview guide were used. After checking the transcripts, an inductive and independent thematic analysis of the interviews was to extract meaningful themes from the dataset.Results: Twelve pain physicians were interviewed. The main obstacles to deprescribing revolved around patient‐specific attributes, characteristics of the opioids themselves, and limitations within the current healthcare system, that hinder optimal patient management. Conversely, patient motivation and education, recourse to hospitalization in a Pain Department with multidisciplinary care, follow‐up by the general practitioner, and training and information dissemination among patients and clinicians emerged as facilitative elements for opioid deprescribing.Conclusion: This study underscores the needs to improve the training of healthcare professionals, the effective communication of pertinent information to patients, and the establishment of a therapeutic partnership with the patient. It is therefore essential to carry out the deprescribing process in a collaborative and interprofessional manner, encompassing both pharmaceutical and non‐pharmaceutical strategies.
- Open Access
- 20 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0305737
DEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol
Introduction: Polypharmacy in patients with advanced cancer represents a major public health problem, leading to risk of iatrogenesis, decrease of quality of life and increase of healthcare costs. In the field of geriatrics, health policies have been developed to address polypharmacy through the use of deprescribing tools. Recently, palliative care initiatives have been introduced, yet these have not fully considered the specificities of this population, particularly their perceptions. It is therefore important to better understand patients’ perceptions of deprescribing in order to adapt tools and actions to make these approaches more effective. Objectives: The aim is to investigate patients’ perceptions of deprescribing in palliative oncology care, and to explore factors that may influence patients’ attitudes and beliefs about deprescribing and to validate a specific questionnaire (rPATD) in this population. An ancillary study will investigate the relationship between patients’ health literacy and their perception of deprescribing. Method: A prospective, observational, multicenter study will be conducted using a sequential mixed exploratory design in a population of patients living with advanced cancer and with a physician-estimated life expectancy of less than 1 year. The study will include an initial qualitative phase. Individual semi-structured interviews using a descriptive approach (thematic analysis) will be conducted (upon saturation). Following analysis of the qualitative data, a quantitative study including 300 patients will be realized to meet secondary objectives. Several data will be collected and 2 self-questionnaires will be administered: the BMQ (beliefs about medicine) and rPATD (perception of deprescribing) possibly supplemented by additional items if required by the qualitative analysis. The auxiliary study will be conducted during this second phase, using a validated self-questionnaire to assess patients’ level of literacy. Conclusion: The disparate outcomes will facilitate the understanding of the perception of deprescribing in palliative oncology care, enabling the development of tailored approaches adapted to this population. Trial registration: ClinicalTrials Identifier: NCT06193083.
- 20 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0305737
Open AccessDEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol
Introduction: Polypharmacy in patients with advanced cancer represents a major public health problem, leading to risk of iatrogenesis, decrease of quality of life and increase of healthcare costs. In the field of geriatrics, health policies have been developed to address polypharmacy through the use of deprescribing tools. Recently, palliative care initiatives have been introduced, yet these have not fully considered the specificities of this population, particularly their perceptions. It is therefore important to better understand patients’ perceptions of deprescribing in order to adapt tools and actions to make these approaches more effective. Objectives: The aim is to investigate patients’ perceptions of deprescribing in palliative oncology care, and to explore factors that may influence patients’ attitudes and beliefs about deprescribing and to validate a specific questionnaire (rPATD) in this population. An ancillary study will investigate the relationship between patients’ health literacy and their perception of deprescribing. Method: A prospective, observational, multicenter study will be conducted using a sequential mixed exploratory design in a population of patients living with advanced cancer and with a physician-estimated life expectancy of less than 1 year. The study will include an initial qualitative phase. Individual semi-structured interviews using a descriptive approach (thematic analysis) will be conducted (upon saturation). Following analysis of the qualitative data, a quantitative study including 300 patients will be realized to meet secondary objectives. Several data will be collected and 2 self-questionnaires will be administered: the BMQ (beliefs about medicine) and rPATD (perception of deprescribing) possibly supplemented by additional items if required by the qualitative analysis. The auxiliary study will be conducted during this second phase, using a validated self-questionnaire to assess patients’ level of literacy. Conclusion: The disparate outcomes will facilitate the understanding of the perception of deprescribing in palliative oncology care, enabling the development of tailored approaches adapted to this population. Trial registration: ClinicalTrials Identifier: NCT06193083.